The first two patients treated in this pivotal trial had previously suffered traumatic peripheral nerve injury resulting in the inability to bend their elbow and significantly impacting basic activities of daily living. An interim review at 20 days post operation for the first two patients to receive CelGro nerve regeneration treatment demonstrated that CelGro is safe and was well tolerated with no inflammatory reactions or complications.
Orthocell Managing Director Paul Anderson said, "This initial assessment is very positive and represents an important step forward in the development of CelGro in the area of human nerve regeneration. CelGro allows for suture-less reconnection of the damaged nerve while guiding nerve regeneration and accelerating the healing process."
Peripheral nerve injury is most commonly caused by accidents or other trauma and in the United States alone more than 20 million people are affected each year at a cost of approximately $150 billion.
CelGro is a biological medical device used in a variety of orthopedic and general reconstructive surgical applications. Orthocell is undertaking a wide range of clinical studies using CelGro to augment tendon, nerve and cartilage repair as well as to guide and promote bone regeneration.
Orthocell has submitted CelGro for first regulatory approval in Europe and expects to receive notice of approval of its CE Mark application in Q1 2017. Orthocell has also submitted a 510(k) application to the U.S. Food and Drug Administration.
Receipt of these approvals will enable commercialisation of CelGro products to commence in Europe and the United States, as well as trigger applications for other regulatory approvals in Australia and Japan in 2017.
Orthocell is an Australian regenerative medicine company developing treatments for tendon, cartilage, and soft tissue injuries.